Khondrion Initiates Pivotal Phase 3 Trial for Sonlicromanol in Rare Mitochondrial Disease
Key Insights
Khondrion (search) has dosed the first patient in its pivotal Phase 3 KHENERFIN study evaluating sonlicromanol for m.3243A>G-related primary mitochondrial disease (search), the most common genetic defect causing this rare condition.
The 52-week randomized trial will enroll up to 220 adult patients across Europe, the UK, and US, with primary endpoints focusing on chronic fatigue (search) and muscle weakness (search) reduction.
Sonlicromanol is a novel brain-penetrant redox-modulator (search) with anti-ferroptotic and anti-inflammatory properties, representing a potential first treatment for this progressive and debilitating condition.
Khondrion (search) has achieved a significant milestone in rare disease drug development with the first patient dosing in its pivotal Phase 3 KHENERFIN study evaluating sonlicromanol for m.3243A>G-related primary mitochondrial disease (search). The 52-week randomized, placebo-controlled trial represents a critical step toward addressing a devastating genetic condition that currently has no approved treatments.
The m.3243A>G mutation represents the most common genetic defect causing primary mitochondrial disease, a progressive and debilitating condition affecting patients across multiple organ systems and often leading to increasing disability over time. Patients experience chronic fatigue (search) and muscle weakness (search) as their most burdensome symptoms, which are often debilitating and impact every area of life.
Novel Therapeutic Approach
Sonlicromanol is an investigational small molecule characterized as a brain-penetrant redox-modulator (search) with anti-ferroptotic and anti-inflammatory properties. The drug's mechanism targets mitochondrial dysfunction (search), positioning it as a potentially differentiated therapeutic option for conditions involving cellular energy metabolism disorders.
"The initiation of patient dosing in our Phase 3 KHENERFIN study marks an important milestone in the development of a potential treatment for patients with m.3243A>G primary mitochondrial disease," said Jasper Levink, CEO of Khondrion (search). "This trial is designed to rigorously evaluate the safety and efficacy of sonlicromanol in a larger, randomized setting, with endpoints reflecting key aspects of disease burden, building on the signals observed in our earlier clinical program."
Trial Design and Endpoints
The KHENERFIN study will enroll up to 220 adult patients aged 18 years and older across Europe, the United Kingdom, and the US with genetically confirmed m.3243A>G primary mitochondrial disease. Participants will be randomized 1:1 to receive either 90 mg sonlicromanol or matching placebo as dispersible tablets twice daily over the 52-week treatment period.
The study features two independent primary endpoints designed to capture the most significant aspects of disease burden: change in NeuroQoL Fatigue Short Form score and performance on the 5-times sit-to-stand test. These endpoints directly address the chronic fatigue (search) and muscle weakness (search) that represent the most bothersome and frequently occurring effects of the disease.
Dr. Mirian Jansen, head of the clinical metabolic department at Radboudumc and principal investigator in the KHENERFIN study, emphasized the trial's patient-centered approach: "This trial is designed to determine whether this investigational therapy can meaningfully impact patient function and fatigue. As investigators, we are committed to advancing this Phase 3 study and working closely with patients to ensure high-quality data collection on outcomes that matter in daily life."
Patient Community Response
The patient advocacy community has expressed significant optimism about the trial's potential impact. Paula Morandi, Chair of International Mito Patients (search) (IMP), which represents 25 mitochondrial disease patient advocacy groups across five continents, stated: "The initiation of the Phase 3 KHENERFIN study by Khondrion (search) is a significant achievement and provides hope to the international mitochondrial disease community. We are encouraged by the progress being made in research and drug development for those living with Primary Mitochondrial Diseases."
Expanding Therapeutic Applications
Beyond rare mitochondrial diseases, Khondrion (search) has also initiated patient dosing in the Phase 2 SON4PEM study, investigating sonlicromanol for post-COVID syndrome (search) with post-exertional malaise (search). This investigator-initiated trial at Amsterdam University Medical Center (search) will enroll approximately 80 adult patients over a 13-week efficacy evaluation period, with the primary endpoint measuring fatigue reduction using the validated Fatigue Assessment Scale.
Jan Smeitink, Khondrion (search)'s founder and Chief Medical Officer, noted the broader implications: "This study represents an important inflection point for Khondrion. At the same time, it reflects our core mission—to develop therapies that make a tangible difference for patients who currently have very limited options."
The parallel development programs demonstrate sonlicromanol's potential applicability across multiple conditions involving mitochondrial dysfunction (search) and cellular energy metabolism disorders, potentially addressing significant unmet medical needs in both rare and more prevalent patient populations.